Molecule Details
| InChIKey | OTBXOEAOVRKTNQ-UHFFFAOYSA-N |
|---|---|
| Canonical SMILES | O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.22 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB00261 |
|---|---|
| Drug Name | Anagrelide |
| CAS Number | 68475-42-3 |
| Groups | approved investigational |
| ATC Codes | L01XX35 |
| Description | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better ... |
Categories: Agents producing tachycardia Antineoplastic Agents Antineoplastic and Immunomodulating Agents Antiplatelet agents Cardiovascular Agents Cytochrome P-450 CYP1A2 Inhibitors Cytochrome P-450 CYP1A2 Inhibitors (weak) Cytochrome P-450 CYP1A2 Substrates Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Decreased Platelet Production Hematologic Agents Heterocyclic Compounds, Fused-Ring Highest Risk QTc-Prolonging Agents Narrow Therapeutic Index Drugs Phosphodiesterase 3 Inhibitors Phosphodiesterase Inhibitors Platelet-reducing Agents QTc Prolonging Agents Thrombocytosis
Cross-references: BindingDB: 50000334 ChEBI: 142290 CHEMBL760 ChemSpider: 2097 Drugs Product Database (DPD): 11707 D07455 PDB: J33 PharmGKB: PA164742986 PubChem:2182 PubChem:46508863 RxCUI: 596724 Therapeutic Targets Database: DAP000612 Wikipedia: Anagrelide ZINC: ZINC000003871541